ערך חשבונאי למניה: MiNK Therapeutics, Inc (INKT)

MiNK Therapeutics, Inc. (INKT) revenues rely on the future sale of iNKT-therapy drugs for cancer treatment. The book value of equity per share on the GURU.Markets system summary chart reflects the asset's dynamics, where the value is maintained at -2.73. The company is actively developing treatments for solid tumors, yet faces fierce competition for leadership within the immuno-oncology niche.

Book value per share reflects the portion of net assets, defined as the difference between the issuer's total equity and liabilities. By analyzing the reference book value per share, investors assess the intrinsic value of the business, which is particularly critical for MiNK Therapeutics, Inc. (INKT), whose capitalization relies on authoritative developments in iNKT cells and innovative oncology treatment methods.